Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:2394 |
Name | ovarian cancer |
Definition | A female reproductive organ cancer that is located_in the ovary. |
Source | DiseaseOntology.org |
Alt Ids | DOID:2144 DOID:0060070 DOID:9595 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer ovarian cancer |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00194714 | Phase Ib/II | HER2 Vaccine | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab | Completed | USA | 0 |
NCT00313599 | Phase I | Lapatinib + Paclitaxel | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT00565851 | Phase III | Gemcitabine Docetaxel + Paclitaxel Carboplatin Bevacizumab | Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 2 |
NCT00892736 | Phase I | Veliparib | Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy | Completed | USA | 0 |
NCT00993655 | Phase III | Cisplatin Paclitaxel Carboplatin | Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Completed | USA | GBR | ESP | CAN | 0 |
NCT01031381 | Phase II | Bevacizumab + Everolimus | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer | Completed | USA | 0 |
NCT01132014 | Phase I | Bevacizumab Dacarbazine | Autologous OC-DC Vaccine in Ovarian Cancer | Completed | USA | 0 |
NCT01218867 | Phase Ib/II | Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin | Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes | Terminated | USA | 0 |
NCT01248949 | Phase I | Bevacizumab MEDI3617 Gemcitabine Carboplatin Paclitaxel | A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT01264432 | Phase I | Veliparib | Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer | Completed | USA | CAN | 0 |
NCT01286987 | Phase I | Talazoparib | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors | Completed | USA | GBR | 0 |
NCT01292655 | Phase I | BMS-906024 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT01305213 | Phase Ib/II | Fosbretabulin Bevacizumab | Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | Completed | USA | 0 |
NCT01312376 | Phase I | Fludarabine Cyclophosphamide Bevacizumab CD3/CD28 stimulated/primed autologous Ts OC-DC vaccine | Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | Terminated | USA | 0 |
NCT01325441 | Phase Ib/II | Napabucasin + Paclitaxel | A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies | Completed | USA | CAN | 0 |
NCT01357161 | Phase II | Carboplatin Adavosertib Paclitaxel | A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004) | Completed | 0 | |
NCT01366144 | Phase I | Paclitaxel Veliparib Carboplatin | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | Active, not recruiting | USA | 0 |
NCT01384253 | Phase I | 212Pb-TCMC-Trastuzumab + Trastuzumab | Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy | Completed | USA | 0 |
NCT01445418 | Phase I | Olaparib Carboplatin | AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer | Completed | USA | 0 |
NCT01459380 | Phase I | Carboplatin Doxorubicin Veliparib Bevacizumab | Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Completed | USA | 0 |
NCT01493505 | Phase III | Carboplatin Paclitaxel Trebananib | TRINOVA-3 | Terminated | USA | NLD | ITA | GRC | ESP | DNK | DEU | CAN | BEL | AUT | 4 |
NCT01551745 | Phase II | Bevacizumab + FANG vaccine | Salvage Ovarian FANG Vaccine + Bevacizumab | Completed | USA | 0 |
NCT01579812 | Phase II | Metformin | Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients | Completed | USA | 0 |
NCT01610206 | Phase II | Gemcitabine + Pazopanib Gemcitabine | A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer | Completed | USA | 0 |
NCT01616303 | Phase II | Carboplatin + Oregovomab + Paclitaxel Carboplatin + Paclitaxel | A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer | Completed | USA | 0 |
NCT01621542 | Phase I | WT2725 | Clinical Study of WT2725 in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT01623349 | Phase I | Alpelisib + Olaparib Buparlisib + Olaparib | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | Completed | USA | 0 |
NCT01652079 | Phase II | Bevacizumab + NLG207 | CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer | Completed | USA | 0 |
NCT01663857 | Phase Ib/II | Ralimetinib Carboplatin + Gemcitabine | A Study of LY2228820 for Recurrent Ovarian Cancer | Completed | USA | DEU | BEL | AUS | 0 |
NCT01730118 | Phase I | HER2 Vaccine | Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing | Completed | USA | 0 |
NCT01831089 | Phase I | Bevacizumab + Lurbinectedin + Paclitaxel Lurbinectedin + Paclitaxel | Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors | Completed | USA | ESP | CHE | 0 |
NCT01847274 | Phase III | Niraparib | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer | Completed | USA | SWE | POL | NOR | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUT | 0 |
NCT01874353 | Phase III | Olaparib | Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy | Active, not recruiting | USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | 4 |
NCT01920061 | Phase I | Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib | A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) | Completed | USA | ITA | GBR | ESP | CAN | 0 |
NCT01928394 | Phase Ib/II | Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab | A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ITA | GBR | FIN | ESP | DNK | DEU | CAN | 0 |
NCT01952249 | Phase Ib/II | Demcizumab Paclitaxel | A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | Terminated | USA | 0 |
NCT01962948 | Phase II | Paclitaxel Ganetespib | Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Terminated | USA | 0 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | NLD | AUS | 0 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Active, not recruiting | USA | NOR | NLD | ITA | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | AUT | AUS | 1 |
NCT01972516 | Phase II | Tivozanib | Tivozanib As Maintenance Therapy In GYN | Terminated | USA | 0 |
NCT01989546 | Phase Ib/II | Talazoparib | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | Completed | USA | 0 |
NCT01995188 | Phase I | Bevacizumab + Carboplatin + DNIB0600A Carboplatin + DNIB0600A | A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer | Completed | USA | 0 |
NCT01999738 | Phase I | EC1456 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02014337 | Phase I | Eribulin + Mifepristone | Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors | Completed | USA | 0 |
NCT02035345 | FDA approved | Carboplatin | Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment | Terminated | USA | 0 |
NCT02046421 | Phase I | Mifepristone Carboplatin + Gemcitabine | Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT02050009 | Phase I | Carboplatin + Metformin + Paclitaxel | Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Withdrawn | USA | 0 |
NCT02068794 | Phase Ib/II | MV-NIS | MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02100007 | Phase Ib/II | ME-344 + Topotecan | ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors | Terminated | USA | GBR | 0 |
NCT02117817 | Phase I | Buparlisib + Nab-paclitaxel | Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer | Withdrawn | 0 | |
NCT02118285 | Phase I | Aldesleukin Epacadostat Cyclophosphamide Fludarabine | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Completed | USA | 0 |
NCT02122809 | Phase I | Chiauranib | Phase I Study of Chiauranib in Patients With Advanced Solid Tumors | Completed | 1 | |
NCT02122861 | Phase I | ID-LV305 | A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | Completed | USA | 0 |
NCT02124421 | Phase II | Carboplatin + Paclitaxel Cisplatin + Paclitaxel | Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT02199171 | Phase I | Carboplatin | Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer | Completed | USA | 0 |
NCT02203513 | Phase II | Prexasertib | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | Terminated | USA | 0 |
NCT02222922 | Phase I | Avelumab + Cofetuzumab pelidotin Fluconazole Cofetuzumab pelidotin | A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | Completed | USA | ESP | 0 |
NCT02264678 | Phase Ib/II | Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | HUN | GBR | FRA | ESP | CAN | BEL | AUS | 1 |
NCT02269293 | Phase I | Carboplatin + Paclitaxel + Selinexor | Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers | Completed | USA | 0 |
NCT02298959 | Phase I | Aflibercept + Pembrolizumab | Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02307240 | Phase I | CUDC-907 | Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | Completed | USA | 0 |
NCT02312245 | Phase II | Topotecan Doxorubicin Paclitaxel Gemcitabine | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Completed | USA | 0 |
NCT02323191 | Phase I | Atezolizumab + Emactuzumab | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | FRA | ESP | BEL | 0 |
NCT02326844 | Phase II | Talazoparib | BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment | Terminated | USA | 0 |
NCT02327078 | Phase Ib/II | Epacadostat + Nivolumab | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | Completed | USA | GBR | 0 |
NCT02335918 | Phase Ib/II | Nivolumab + Varlilumab | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT02340611 | Phase II | Cediranib + Olaparib | A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib | Completed | CAN | 0 |
NCT02341625 | Phase Ib/II | BMS-986148 BMS-986148 + Nivolumab | A Study of BMS-986148 in Patients With Select Advanced Solid Tumors | Terminated | USA | NLD | ITA | GBR | CAN | BEL | AUS | 0 |
NCT02346747 | Phase II | FANG vaccine | Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL) | Active, not recruiting | USA | 0 |
NCT02346955 | Phase I | CM-24 CM-24 + Pembrolizumab | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | Terminated | USA | ISR | 0 |
NCT02349958 | Phase II | Mitomycin C Cisplatin Doxorubicin | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy | Unknown status | USA | 0 |
NCT02387125 | Phase I | CMB305 | A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Terminated | USA | 0 |
NCT02417753 | Phase II | Danvatirsen | AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites | Terminated | USA | 0 |
NCT02419417 | Phase Ib/II | BMS986158 Paclitaxel | Study of BMS-986158 in Subjects With Select Advanced Solid Tumors | Completed | USA | FRA | ESP | CAN | AUS | 0 |
NCT02432690 | Phase II | Amcasertib | A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation | Terminated | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
NCT02437812 | Phase II | Paclitaxel Carboplatin Metformin | Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma | Unknown status | USA | 0 |
NCT02446600 | Phase III | Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin | Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | CAN | 2 |
NCT02452424 | Phase Ib/II | Pembrolizumab + Pexidartinib | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Terminated | USA | 0 |
NCT02452775 | Phase I | OC-L | Autologous OC-L Vaccine and Ovarian Cancer | Terminated | USA | 0 |
NCT02476968 | FDA approved | Olaparib | To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer (ORZORA) | Completed | POL | ITA | HUN | GBR | ESP | CZE | CAN | BGR | 0 |
NCT02487095 | Phase Ib/II | Berzosertib Topotecan | Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer | Active, not recruiting | USA | 0 |
NCT02498600 | Phase II | Ipilimumab Nivolumab | Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02502266 | Phase II | Topotecan Paclitaxel Doxorubicin Olaparib Cediranib | Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | CAN | 3 |
NCT02520154 | Phase II | Carboplatin + Paclitaxel Pembrolizumab | Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT02554812 | Phase Ib/II | Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Terminated | USA | POL | GBR | FRA | CAN | AUS | 2 |
NCT02558348 | Phase Ib/II | Anlotinib | Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001) | Terminated | USA | 0 |
NCT02575781 | Phase I | SAR428926 | A Study of SAR428926 in Patients With Advanced Solid Tumors | Completed | FRA | ESP | DNK | 0 |
NCT02575807 | Phase Ib/II | Epacadostat CRS-207 | Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer | Terminated | USA | CAN | 0 |
NCT02580058 | Phase III | Doxorubicin Avelumab | A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer | Completed | USA | POL | NOR | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | CZE | CHE | CAN | BEL | AUT | AUS | 6 |
NCT02584478 | Phase Ib/II | Anlotinib + Carboplatin + Paclitaxel | Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | Active, not recruiting | USA | ITA | GBR | ESP | 2 |
NCT02595892 | Phase II | Berzosertib Gemcitabine | Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT02606305 | Phase I | Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine | Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer | Completed | USA | ESP | CAN | BEL | 0 |
NCT02627430 | Phase I | Onalespib + Talazoparib | Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer | Withdrawn | 0 | |
NCT02627443 | Phase II | Carboplatin + Gemcitabine Berzosertib | Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT02628535 | Phase I | Obrindatamab | Safety Study of MGD009 in B7-H3-expressing Tumors | Terminated | USA | CAN | AUS | 0 |
NCT02631876 | Phase II | Paclitaxel + Pegylated liposomal doxorubicin Gemcitabine Topotecan Mirvetuximab Soravtansine | PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer | Completed | USA | ITA | IRL | GBR | FRA | ESP | CZE | CHE | CAN | BEL | 3 |
NCT02632448 | Phase Ib/II | Gemcitabine + LY2880070 LY2880070 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | Recruiting | USA | POL | HRV | CAN | 0 |
NCT02646319 | Phase I | Nab-rapamycin | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations | Completed | USA | 0 |
NCT02649673 | Phase Ib/II | LCL161 + Topotecan | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies | Terminated | USA | 0 |
NCT02655016 | Phase III | Niraparib | A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy | Active, not recruiting | USA | SWE | POL | NOR | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BEL | 2 |
NCT02658214 | Phase I | Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | Completed | 2 | |
NCT02681237 | Phase I | Cediranib + Olaparib | A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer | Completed | CAN | 0 |
NCT02725489 | Phase II | Durvalumab + FANG vaccine | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | Completed | USA | 0 |
NCT02734004 | Phase Ib/II | Durvalumab + Olaparib Bevacizumab + Durvalumab + Olaparib | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) | Active, not recruiting | USA | NLD | ISR | GBR | FRA | CHE | 1 |
NCT02737787 | Phase I | Nivolumab + WT1 vaccine Nivolumab + NY-ESO-1 peptide vaccine | A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer | Completed | USA | 0 |
NCT02760797 | Phase I | Emactuzumab + Selicrelumab | A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | FRA | BEL | 0 |
NCT02762981 | Phase Ib/II | Nab-paclitaxel + Relacorilant | Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors | Completed | USA | 0 |
NCT02799095 | Phase I | ALKS 4230 | A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors | Completed | USA | POL | ESP | CAN | BEL | AUS | 1 |
NCT02839707 | Phase II | Atezolizumab + Bevacizumab + Pegylated liposomal doxorubicin Atezolizumab + Pegylated liposomal doxorubicin Bevacizumab + Pegylated liposomal doxorubicin | Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Active, not recruiting | USA | 1 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02923349 | Phase Ib/II | INCAGN01949 | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | CHE | 0 |
NCT02950064 | Phase I | BTP-114 | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | Unknown status | USA | 0 |
NCT02952248 | Phase I | Ezabenlimab | A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours | Completed | USA | GBR | CAN | 0 |
NCT02953782 | Phase Ib/II | Cetuximab + Hu5F9-G4 | Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02996825 | Phase I | Gemcitabine + Mirvetuximab Soravtansine | Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer | Completed | USA | 0 |
NCT03023319 | Phase I | Bosutinib + Pemetrexed Disodium | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | Completed | USA | 0 |
NCT03026062 | Phase II | Tremelimumab Durvalumab + Tremelimumab Durvalumab | Durvalumab and Tremelimumab in Combo Versus Sequential | Active, not recruiting | USA | 0 |
NCT03029598 | Phase Ib/II | Carboplatin + Pembrolizumab | Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Completed | USA | 0 |
NCT03030287 | Phase I | Navicixizumab + Paclitaxel | A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | Completed | USA | 0 |
NCT03056833 | Phase I | Carboplatin + Paclitaxel + Ribociclib | Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer | Completed | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03132922 | Phase I | afamitresgene autoleucel | MAGE-A4c1032T for Multi-Tumor | Active, not recruiting | USA | CAN | 0 |
NCT03150810 | Phase Ib/II | Pamiparib + Temozolomide | Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | AUS | 0 |
NCT03154281 | Phase I | Everolimus + Niraparib | Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast | Completed | USA | 0 |
NCT03162627 | Phase I | Olaparib + Selumetinib | Selumetinib and Olaparib in Solid Tumors | Active, not recruiting | USA | 0 |
NCT03188965 | Phase I | Elimusertib | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Completed | USA | GBR | CHE | CAN | 3 |
NCT03199586 | Phase I | NP-G2-044 | Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma) | Completed | USA | 0 |
NCT03206177 | Phase I | Carboplatin + Galunisertib + Paclitaxel | Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary | Completed | USA | 0 |
NCT03239145 | Phase I | Pembrolizumab + Trebananib | Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Active, not recruiting | USA | 0 |
NCT03264664 | Phase I | E7386 | Study of E7386 in Participants With Selected Advanced Neoplasms | Active, not recruiting | USA | GBR | 0 |
NCT03283943 | Phase I | Durvalumab | PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. | Unknown status | CAN | 0 |
NCT03292172 | Phase I | Atezolizumab + TEN-010 | A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer | Terminated | USA | GBR | DNK | CAN | AUS | 0 |
NCT03294694 | Phase I | Fulvestrant + Ribociclib + Spartalizumab Ribociclib + Spartalizumab | Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | Terminated | USA | 0 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03330405 | Phase II | Avelumab + Talazoparib | Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors | Terminated | USA | HUN | GBR | DNK | CAN | BEL | AUS | 2 |
NCT03342417 | Phase II | Ipilimumab + Nivolumab | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | Terminated | USA | 0 |
NCT03353831 | Phase III | Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Atezolizumab + Bevacizumab + Pegylated liposomal doxorubicin Atezolizumab + Bevacizumab + Paclitaxel | Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer | Active, not recruiting | SWE | NOR | LTU | FRA | FIN | EST | ESP | DNK | DEU | CHE | BEL | AUT | 0 |
NCT03363776 | Phase Ib/II | BMS-986277 BMS-986277 + Nivolumab | An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers | Terminated | USA | CAN | 0 |
NCT03363893 | Phase Ib/II | Samuraciclib Fulvestrant + Samuraciclib | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | Completed | USA | GBR | 0 |
NCT03412877 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL Aldesleukin + Cyclophosphamide + Fludarabine + iTCR-transduced PBL + Pembrolizumab | Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer | Recruiting | USA | 0 |
NCT03430700 | Phase II | Pembrolizumab | Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer (PROMPT) | Active, not recruiting | GBR | 0 |
NCT03449108 | Phase II | Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna | Iovance Alliance: LN-145 Across Multiple Tumor Types | Active, not recruiting | USA | 0 |
NCT03456700 | Phase II | Auranofin + Sirolimus | Auranofin and Sirolimus in Treating Participants With Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT03458221 | Phase II | Itraconazole Everolimus Letrozole Bicalutamide | Signal TrAnsduction Pathway Activity Analysis in OVarian cancER (STAPOVER) | Recruiting | NLD | 0 |
NCT03508570 | Phase I | Nivolumab Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | Completed | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03539328 | Phase II | Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin Gemcitabine + Paclitaxel + Pegylated liposomal doxorubicin + Pembrolizumab | Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer (MITO27) | Unknown status | ITA | 0 |
NCT03552471 | Phase I | Mirvetuximab Soravtansine + Rucaparib | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT03565445 | Phase I | ASP1948 + Nivolumab ASP1948 | A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors | Completed | USA | ITA | GBR | ESP | CAN | 4 |
NCT03610490 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
NCT03621982 | Phase I | Camidanlumab tesirine | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Terminated | USA | GBR | BEL | 0 |
NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Active, not recruiting | USA | AUS | 0 |
NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | AUS | 0 |
NCT03639246 | Phase Ib/II | AVB-S6-500 + Paclitaxel AVB-S6-500 + Pegylated liposomal doxorubicin Paclitaxel Pegylated liposomal doxorubicin | Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer | Completed | USA | 0 |
NCT03663712 | Phase I | Talimogene laherparepvec | Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) | Completed | USA | 0 |
NCT03665285 | Phase Ib/II | NC318 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT03667716 | Phase I | COM701 COM701 + Nivolumab | COM701 in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03674567 | Phase Ib/II | FLX475 + Pembrolizumab FLX475 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | Active, not recruiting | USA | AUS | 4 |
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT03717415 | Phase Ib/II | Carboplatin + Rebastinib | A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT03719326 | Phase I | Eganelisib + Etrumadenant + Pegylated liposomal doxorubicin Etrumadenant + Pegylated liposomal doxorubicin | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | Completed | USA | AUS | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Completed | USA | NLD | GBR | FRA | FIN | ESP | 0 |
NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Completed | USA | 0 |
NCT03784378 | Phase I | RXDX-105 | Continued Access to RXDX-105 | Completed | USA | 0 |
NCT03797326 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Completed | USA | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | AUS | ARG | 6 |
NCT03815682 | Phase I | Pembrolizumab + RPTR-147 RPTR-147 | RPTR-147 in Patients With Selected Solid Tumors and Lymphomas | Terminated | USA | 0 |
NCT03872947 | Phase I | Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT03875820 | Phase I | Defactinib + RO5126766 | Phase I Trial of Defactinib and VS-6766. (FRAME) | Active, not recruiting | GBR | 0 |
NCT03891576 | Phase II | Niraparib | Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) (Newton) | Active, not recruiting | ITA | DEU | 0 |
NCT03907527 | Phase I | PRGN-3005 | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Active, not recruiting | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT03944902 | Phase I | Niraparib + Telaglenastat | CB-839 in Combination With Niraparib in Platinum Resistant BRCA -Wild-type Ovarian Cancer Patients (BRCA) | Terminated | USA | 0 |
NCT03968406 | Phase I | Talazoparib | Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers | Recruiting | USA | 0 |
NCT03970382 | Phase I | NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | Suspended | USA | 0 |
NCT03990233 | Phase I | Effi-DEM Effi-DEM + Ezabenlimab | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Active, not recruiting | FRA | BEL | 0 |
NCT03992131 | Phase Ib/II | Lucitanib + Rucaparib Rucaparib + Sacituzumab govitecan-hziy | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) | Terminated | USA | 0 |
NCT03997968 | Phase Ib/II | CYT01B | A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04041128 | Phase I | Olaparib | PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer | Completed | USA | 0 |
NCT04044859 | Phase I | afamitresgene autoleucel afamitresgene autoleucel + Pembrolizumab afamitresgene autoleucel + Nivolumab | ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | Recruiting | USA | ESP | CAN | BEL | 0 |
NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Completed | USA | 0 |
NCT04091204 | Phase II | Olaparib | Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study (MITO 31) | Recruiting | ITA | 0 |
NCT04095273 | Phase I | Elimusertib + Pembrolizumab | Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug | Completed | USA | GBR | ESP | DEU | CHE | 0 |
NCT04105335 | Phase I | CEBPA-51 + Pembrolizumab | A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (TIMEPOINT) | Active, not recruiting | GBR | 0 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04148937 | Phase I | LY3475070 LY3475070 + Pembrolizumab | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Completed | USA | GBR | AUS | 0 |
NCT04152018 | Phase I | PF-06801591 + PF-06940434 PF-06940434 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Active, not recruiting | USA | SVK | AUS | 2 |
NCT04169841 | Phase II | Durvalumab + Olaparib + Tremelimumab | Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) | Active, not recruiting | FRA | 0 |
NCT04235101 | Phase I | Niraparib + Trastuzumab Duocarmazine | Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors | Completed | NLD | GBR | BEL | 0 |
NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT04244552 | Phase I | ATRC-101 | First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Terminated | USA | 0 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |
NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Completed | USA | GBR | ESP | DEU | 1 |
NCT04260802 | Phase Ib/II | OC-001 + unspecified PD-L1 antibody OC-001 + unspecified PD-1 antibody OC-001 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | Recruiting | CAN | 0 |
NCT04261465 | Phase II | Carboplatin + Olaparib + Paclitaxel | NUVOLA TRIAL Open-label Multicentre Study (NUVOLA) | Unknown status | ITA | 0 |
NCT04282018 | Phase Ib/II | BGB-10188 + Zanubrutinib BGB-10188 + Tislelizumab BGB-10188 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Completed | AUS | 1 |
NCT04367675 | Phase I | INO-5401 INO-5401 + INO-9012 | INO 5401 Vaccination in BRCA1/2 Mutation Carriers | Recruiting | USA | 0 |
NCT04375956 | Phase II | Pembrolizumab | Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients (MITO 27) | Recruiting | ITA | 0 |
NCT04377087 | Phase II | Olaparib | Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer | Terminated | USA | 0 |
NCT04387227 | Phase II | Carboplatin + Pembrolizumab | Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Recruiting | USA | 0 |
NCT04389632 | Phase I | SGN-B6A | A Study of SGN-B6A in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CHE | 1 |
NCT04395079 | Phase II | Tremelimumab Durvalumab | Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies | Active, not recruiting | USA | 0 |
NCT04396821 | Phase I | TST001 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT04406623 | Phase I | SL-172154 | Phase 1 Study of SL-172154 (SIRPalpha-Fc-CD40L) in Subjects With Ovarian Cancer | Completed | USA | 0 |
NCT04423029 | Phase Ib/II | DF6002 DF6002 + Nivolumab | A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 0 |
NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
NCT04434482 | Phase I | Senaparib + Temozolomide | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | Completed | USA | AUS | 3 |
NCT04491942 | Phase I | Cisplatin + Elimusertib Cisplatin + Elimusertib + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT04493619 | Phase Ib/II | Carboplatin + PLX2853 PLX2853 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer | Terminated | USA | CAN | 0 |
NCT04502602 | Phase I | Neratinib + Niraparib | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer (iNNOVATE) | Recruiting | USA | 0 |
NCT04511845 | Phase I | SPYK04 | A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). | Active, not recruiting | USA | 1 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04550494 | Phase II | Talazoparib | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations | Recruiting | USA | 0 |
NCT04561362 | Phase Ib/II | BT8009 BT8009 + Pembrolizumab | Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04580485 | Phase I | INCB106385 + Retifanlimab INCB106385 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | BEL | 0 |
NCT04592653 | Phase Ib/II | ALKS 4230 ALKS 4230 + Pembrolizumab | Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3) (ARTISTRY-3) | Active, not recruiting | USA | ESP | 0 |
NCT04602117 | Phase I | Paclitaxel + Trastuzumab Duocarmazine | Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | Withdrawn | USA | 0 |
NCT04606381 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 | A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) | Active, not recruiting | USA | GBR | CAN | 1 |
NCT04608409 | Phase I | Lapatinib + Paclitaxel | Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT04609579 | Phase I | SNX281 Pembrolizumab + SNX281 | Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | Terminated | USA | 0 |
NCT04616534 | Phase I | Elimusertib + Gemcitabine | Testing the Addition of an Anti-cancer Drug, BAY 1895344 ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT04641247 | Phase II | Niraparib | A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Active, not recruiting | USA | ITA | ISR | FRA | ESP | DNK | CAN | AUT | 0 |
NCT04644289 | Phase II | Olaparib Durvalumab + Olaparib | WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC (WoO) | Recruiting | DEU | 0 |
NCT04665921 | Phase I | SGN-STNV | A Study of SGN-STNV in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04673448 | Phase I | Dostarlimab-gxly + Niraparib | Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer | Recruiting | USA | 0 |
NCT04676334 | Phase III | Rucaparib | CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib (CATCH-R) | Completed | POL | ITA | ISR | GBR | CAN | 1 |
NCT04679064 | Phase III | Bevacizumab + Gemcitabine Dostarlimab-gxly + Niraparib Pegylated liposomal doxorubicin Bevacizumab + Topotecan Paclitaxel Topotecan Bevacizumab + Paclitaxel Bevacizumab + Pegylated liposomal doxorubicin Gemcitabine | Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment (NItCHE-MITO33) | Recruiting | ITA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04695847 | Phase I | M1231 | M1231 in Participants With Solid Tumors | Completed | USA | CAN | 0 |
NCT04707248 | Phase I | Raludotatug deruxtecan | A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors | Recruiting | USA | 1 |
NCT04711161 | Phase I | GRN-300 GRN-300 + Paclitaxel | First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. | Suspended | USA | 0 |
NCT04731467 | Phase Ib/II | CM-24 + Nivolumab CM-24 + Nab-paclitaxel + Nivolumab | A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors | Active, not recruiting | USA | ISR | ESP | 0 |
NCT04739800 | Phase II | Paclitaxel + Pegylated liposomal doxorubicin + Topotecan Cediranib + Durvalumab Cediranib + Olaparib Cediranib + Durvalumab + Olaparib | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | Active, not recruiting | USA | 1 |
NCT04752826 | Phase Ib/II | BI-1808 + Pembrolizumab BI-1808 | BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20) | Recruiting | USA | SWE | HUN | GBR | DNK | 1 |
NCT04787042 | Phase Ib/II | Pembrolizumab + ST-067 ST-067 Obinutuzumab + ST-067 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Recruiting | USA | 0 |
NCT04826198 | Phase Ib/II | AsiDNA + Niraparib | Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to Niraparib in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With Niraparib (REVOCAN) | Terminated | FRA | 0 |
NCT04837196 | Phase Ib/II | ASP7517 + Pembrolizumab ASP7517 | Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen | Completed | USA | 0 |
NCT04851834 | Phase Ib/II | Cisplatin + NTX-301 NTX-301 NTX-301 + Temozolomide Carboplatin + NTX-301 | NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma | Terminated | AUS | 0 |
NCT04890613 | Phase I | CX-5461 | Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Recruiting | USA | CAN | 0 |
NCT04907968 | Phase Ib/II | Carboplatin + XMT-1536 | Study of Upifitamab Rilsodotin in Combination With Other Agent(s) in Participants With High-grade Serous Ovarian Cancer (UPGRADE) | Terminated | USA | 0 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |
NCT04939701 | Phase Ib/II | ASP0739 + Pembrolizumab ASP0739 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants | Terminated | USA | 0 |
NCT04969835 | Phase I | AVA6000 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Recruiting | USA | GBR | 0 |
NCT04972981 | Phase I | ADCT-901 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors | Active, not recruiting | USA | GBR | ESP | 0 |
NCT04992013 | Phase II | Niraparib | Niraparib in Tumors Metastatic to the CNS | Recruiting | USA | 0 |
NCT05000294 | Phase Ib/II | Atezolizumab + Tivozanib | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | Recruiting | USA | 0 |
NCT05001282 | Phase Ib/II | ELU001 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) | Terminated | USA | 0 |
NCT05001347 | Phase II | Uliledlimab | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ) in Patients With Ovarian Cancer and Selected Solid Tumors | Completed | USA | 0 |
NCT05038150 | Phase I | SGN1 | Study of SGN1 in Patients With Advanced Solid Tumor | Recruiting | USA | 1 |
NCT05041972 | Phase II | ARX-788 | ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) | Withdrawn | USA | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |
NCT05067972 | Phase I | PF-07260437 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001) | Terminated | USA | 1 |
NCT05071937 | Phase II | Talazoparib + ZEN-3694 | ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer | Recruiting | USA | 0 |
NCT05082025 | Phase II | Copanlisib + Fulvestrant | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | Active, not recruiting | USA | 0 |
NCT05092373 | Phase I | Cabozantinib Atezolizumab + Nab-paclitaxel | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | Recruiting | USA | 0 |
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Terminated | NLD | FRA | 0 |
NCT05103345 | Phase I | SGN1 | Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor | Recruiting | 2 | |
NCT05104515 | Phase I | OVM-200 | First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine | Recruiting | GBR | 0 |
NCT05118841 | Phase I | ZX-4081 | Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | Unknown status | USA | 0 |
NCT05123482 | Phase Ib/II | AZD8205 | First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies | Recruiting | USA | POL | NLD | ITA | HUN | GBR | ESP | CAN | BEL | AUS | 5 |
NCT05180474 | Phase Ib/II | GEN1047 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DNK | BEL | 0 |
NCT05185947 | Phase II | Nilotinib + Paclitaxel | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Ovarian, Colorectal, or Appendiceal Cancer | Active, not recruiting | USA | 0 |
NCT05200364 | Phase I | Bevacizumab + Luveltamab Tazevibulin | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | Recruiting | USA | 0 |
NCT05200559 | Phase Ib/II | E7777 + Pembrolizumab | T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05208762 | Phase I | SGN-PDL1V | A Study of SGN-PDL1V in Advanced Solid Tumors | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 0 |
NCT05229900 | Phase I | SGN-ALPV | A Study of SGN-ALPV in Advanced Solid Tumors | Terminated | USA | SWE | GBR | ESP | CAN | 0 |
NCT05252390 | Phase Ib/II | NUV-868 NUV-868 + Olaparib Enzalutamide + NUV-868 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05252416 | Phase Ib/II | BLU-222 + Carboplatin BLU-222 + Fulvestrant + Ribociclib BLU-222 + Fulvestrant | (VELA) Study of BLU-222 in Advanced Solid Tumors | Recruiting | USA | ITA | GBR | 0 |
NCT05255471 | Phase III | Carboplatin + Paclitaxel Olaparib Carboplatin + Pegylated liposomal doxorubicin Carboplatin + Gemcitabine | MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. (MITO 35B) | Recruiting | ITA | 0 |
NCT05256381 | Phase II | Pembrolizumab + SOT101 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | Active, not recruiting | USA | POL | ITA | HUN | FRA | ESP | CZE | BEL | 1 |
NCT05259696 | Phase Ib/II | E-602 E-602 + Pembrolizumab | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (GLIMMER-01) | Active, not recruiting | USA | 0 |
NCT05262530 | Phase Ib/II | BNT142 | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors | Recruiting | USA | GBR | ESP | 1 |
NCT05263180 | Phase I | EMB-09 | A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors. | Recruiting | AUS | 1 |
NCT05271318 | Phase I | Pembrolizumab + TILT-123 | Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Ovarian Cancer (PROTA) | Recruiting | USA | FIN | 0 |
NCT05276973 | Phase I | Carboplatin + Ipatasertib + Paclitaxel | Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer | Recruiting | USA | 0 |
NCT05281471 | Phase III | Bevacizumab + Carboplatin Bevacizumab + Cisplatin Bevacizumab + Carboplatin + GL-ONC1 Bevacizumab + Cisplatin + GL-ONC1 | Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime) | Recruiting | USA | 0 |
NCT05293496 | Phase I | MGC018 + MGD019 | A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05295589 | Phase II | Topotecan Pegylated liposomal doxorubicin Copanlisib + Olaparib Paclitaxel | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | Withdrawn | USA | 0 |
NCT05298592 | Phase I | BMS-986406 + Nivolumab BMS-986406 | A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors | Completed | USA | ESP | BEL | ARG | 2 |
NCT05306444 | Phase I | HBM7008 | CLN-418 Study on Subjects With Advanced Solid Tumors | Completed | USA | AUS | 0 |
NCT05307874 | Phase Ib/II | Aldesleukin + ICT01 | Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2) | Recruiting | FRA | 0 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05360680 | Phase I | CUE-102 | A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers | Active, not recruiting | USA | 0 |
NCT05368506 | Phase I | ZN-c3 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer | Withdrawn | 0 | |
NCT05394103 | Phase Ib/II | Q901 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05394675 | Phase I | DS-9606a | A Study of DS-9606a in Patients With Advanced Solid Tumors | Recruiting | USA | GBR | 0 |
NCT05417594 | Phase Ib/II | AZD9574 AZD9574 + Temozolomide | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) | Recruiting | USA | SWE | GBR | ESP | DEU | AUS | 1 |
NCT05427487 | Phase I | IVX037 | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Recruiting | AUS | 0 |
NCT05496595 | Phase I | DCBY02 | DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Active, not recruiting | USA | AUS | 0 |
NCT05523440 | Phase II | Bevacizumab + Niraparib Niraparib | Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation | Recruiting | USA | 0 |
NCT05554328 | Phase II | Selumetinib Olaparib + Selumetinib | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | Recruiting | USA | 1 |
NCT05568680 | Phase I | SynKIR-110 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Recruiting | USA | 0 |
NCT05572684 | Phase Ib/II | NC410 + Pembrolizumab | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05607498 | Phase I | EMB-07 | First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors | Recruiting | AUS | 1 |
NCT05613088 | Phase II | Paclitaxel + Pegylated liposomal doxorubicin + Topotecan MORAb-202 | A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | ITA | ISR | ESP | BEL | AUS | 3 |
NCT05617755 | Phase I | AB-1015 | AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT05642780 | Phase II | Pembrolizumab + SKB264 | SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | Recruiting | USA | POL | CAN | BEL | AUS | 1 |
NCT05642949 | Phase Ib/II | MHB036C | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05650203 | Phase I | JS006 + JS009 + Toripalimab-tpzi JS009 | A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies | Withdrawn | 0 | |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | AUS | 0 |
NCT05662397 | Phase Ib/II | HST-1011 Cemiplimab + HST-1011 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | Recruiting | USA | 0 |
NCT05683418 | Phase I | TOS-358 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors | Recruiting | USA | 0 |
NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05694715 | Phase I | Irinotecan + Niraparib | Combination Therapy in Cancers With Mutations in DNA Repair Genes | Recruiting | USA | 0 |
NCT05719558 | Phase I | ASP1002 | A Study of ASP1002 in Adults for Treatment of Solid Tumors | Recruiting | USA | 0 |
NCT05720117 | Phase I | PYX-201 | Study of PYX-201 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05733000 | Phase II | CPI-613 + Gemcitabine + Hydroxychloroquine CPI-613 + Hydroxychloroquine CPI-613 + Gemcitabine CPI-613 + Fluorouracil + Hydroxychloroquine | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | Recruiting | USA | 0 |
NCT05746897 | Phase I | NM1F + Pembrolizumab NM1F | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05756907 | Phase Ib/II | Atezolizumab + SON-1010 SON-1010 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | Recruiting | USA | AUS | 0 |
NCT05785754 | Phase I | DCSZ11 | DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
NCT05821777 | Phase Ib/II | LB101 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT05848739 | Phase I | ST316 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05875168 | Phase Ib/II | DS-3939a | First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | BEL | 1 |
NCT05891171 | Phase I | AB598 + Carboplatin + Pemetrexed Disodium + Zimberelimab AB598 AB598 + Fluorouracil + Leucovorin + Oxaliplatin + Zimberelimab | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25) | Recruiting | USA | AUS | 0 |
NCT05922930 | Phase Ib/II | TROP2-CAR/IL15-transduced CBNK cells Cyclophosphamide + Fludarabine | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer | Recruiting | USA | 0 |
NCT05932862 | Phase I | ISM3091 | First-in Human Phase I Study of ISM3091 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05934539 | Phase Ib/II | ALG.APV-527 | ALG.APV-527 First-in-human Study | Recruiting | USA | 0 |
NCT05942300 | Phase I | Carboplatin + Tulmimetostat | CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer | Recruiting | USA | 0 |
NCT05947474 | Phase I | ORB-011 | ORB-011 In Patients With Advanced Solid Tumors (ORB) | Recruiting | USA | 0 |
NCT05964361 | Phase Ib/II | IL15-TransDC | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients | Recruiting | BEL | 0 |
NCT05985083 | Phase I | IMM47 | A Study Of IMM47 In Subjects With Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT05989724 | Phase I | SON-DP | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06003231 | Phase II | Disitamab vedotin | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 1 |
NCT06014502 | Phase I | IMGS-001 | Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06036121 | Phase I | ADRX-0706 | A Study of ADRX-0706 in Select Advanced Solid Tumors | Recruiting | USA | 1 |
NCT06051695 | Phase Ib/II | A2B694 | A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2) | Recruiting | USA | 0 |
NCT06052852 | Phase Ib/II | BDC-3042 + Pembrolizumab BDC-3042 | Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies | Recruiting | USA | 0 |
NCT06056323 | Phase Ib/II | HB0045 | A Study of HB0045 Injection in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06072781 | Phase III | Paclitaxel Pegylated liposomal doxorubicin Defactinib + RO5126766 Topotecan Anastrozole Letrozole | A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301) | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 0 |
NCT06090266 | Phase Ib/II | Cemiplimab + OR502 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | Recruiting | USA | 0 |
NCT06107868 | Phase I | Carboplatin + Paclitaxel + RP-6306 | Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer (GyneRep) | Active, not recruiting | CAN | 0 |
NCT06108479 | Phase I | DF6215 | Study of DF6215 in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | AUS | 0 |
NCT06120972 | Phase II | Olaparib | Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency | Recruiting | USA | 0 |
NCT06154291 | Phase Ib/II | XON7 | FIH XON7 in Advanced/Metastatic Solid Tumors (FIPO23) | Recruiting | FRA | BEL | 0 |
NCT06171178 | Phase I | ASP1012 + Pembrolizumab ASP1012 | A Study of ASP1012 in Adults With Solid Tumors | Recruiting | USA | 0 |
NCT06171789 | Phase Ib/II | PRO1107 | PRO1107 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06234423 | Phase I | CUSP06 | A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06238479 | Phase I | LY4101174 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | BEL | AUS | 1 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | AUS | 0 |
NCT06253520 | Phase I | Cyclophosphamide + Fludarabine Aldesleukin + Anti-KRAS G12V TCR cells + GRT-C903 + GRT-R904 Aldesleukin + Anti-KRAS G12D TCR cells + GRT-C903 + GRT-R904 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | Recruiting | USA | 0 |
NCT06264921 | Phase I | NKT3447 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06274437 | Phase I | BND-35 + Cetuximab BND-35 + Nivolumab BND-35 | A Study of BND-35 in Participants With Advanced Solid Tumors | Recruiting | ISR | 0 |
NCT06276491 | Phase I | XmAb541 | Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06279130 | Phase II | Balstilimab Balstilimab + Botensilimab | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (NEOASIS) | Recruiting | NLD | 0 |
NCT06293898 | Phase I | BL-M07D1 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Recruiting | USA | 0 |
NCT06303505 | Phase Ib/II | TUB-040 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC (NAPISTAR1-01) | Recruiting | USA | ESP | DEU | BEL | 1 |
NCT06342986 | FT536 Cyclophosphamide + Fludarabine | Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | Recruiting | USA | 0 | |
NCT06380816 | Phase Ib/II | UCB4594 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | Recruiting | GBR | 0 |
NCT06399757 | Phase Ib/II | APL-5125 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06400472 | Phase I | LY4170156 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | Recruiting | USA | FRA | ESP | AUS | 2 |
NCT06412120 | FDA approved | Niraparib | Study Evaluating Safety, Tolerability, and Metabolism of Niraparib | Not yet recruiting | USA | 0 |
NCT06416436 | Phase I | Atezolizumab | Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | Not yet recruiting | USA | 0 |
NCT06458712 | Phase I | DSB2455 | Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies | Recruiting | ESP | 0 |
NCT06465069 | Phase I | LY4052031 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01) | Recruiting | USA | GBR | ESP | 1 |
NCT06466187 | Phase I | SGN-MesoC2 | A Study of SGN-MesoC2 in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06515613 | Phase I | CTIM-76 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06526819 | Phase Ib/II | SMP-3124 | A Phase 1/2 Study of SMP-3124LP in Adults With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT06533332 | Phase I | ERX-315 | A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | Recruiting | AUS | 0 |
NCT06548672 | Phase I | BC3195 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer | Recruiting | USA | 0 |
NCT06582017 | Phase I | QXL138AM | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Recruiting | USA | 0 |
NCT06586957 | Phase I | NKT3964 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06597721 | Phase I | AMT-754 | AMT-754 in Patients With Selected Advanced Solid Tumours | Not yet recruiting | AUS | 0 |
NCT06620029 | Phase Ib/II | BMX-001 + Paclitaxel | BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer | Not yet recruiting | USA | 0 |
NCT06630325 | Phase II | Fulvestrant Olaparib + Pegylated liposomal doxorubicin Abemaciclib + Letrozole Abemaciclib Olaparib Olaparib + Temozolomide Abemaciclib + Tamoxifen Abemaciclib + Gemcitabine Gefitinib Abemaciclib + Pemetrexed Disodium Abemaciclib + Exemestane Osimertinib Carboplatin + Gefitinib + Pemetrexed Disodium Carboplatin + Olaparib + Paclitaxel | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | Not yet recruiting | USA | 0 |
NCT06646627 | Phase I | B7-H3 CAR T cells | Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors | Not yet recruiting | USA | 0 |
NCT06651593 | Phase II | BND-22 + Cemiplimab | Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors | Not yet recruiting | USA | 0 |